Rama K. Mallampalli, MD
Dr. Mallampalli is an internationally recognized investigator in the area of lipid metabolism and ubiquitin-mediated proteolysis as it relates to inflammation and injury. His research program discovered a unique model for the molecular behavior of ubiquitin E3 ligase subunits that control inflammation. Dr. Mallampalli’s laboratory designed, synthesized, and tested the first-in-class genus of ubiquitin E3 ligase (F box) inhibitors that modulate proteolysis thereby inhibiting inflammation in preclinical models of ALI and multi-organ failure.
Beibei Bill Chen, PhD
Dr. Chen’s primary research interest includes the study of the molecular mechanisms that control inflammation and cell proliferation via protein ubiquitination. Specifically, over the last four years, he has successfully identified and characterized over 10 novel ubiquitin E3 ligases. Dr. Chen’s second area of research interest is in the small molecule drug design. He has successfully designed and synthesized a novel series of first-in-class small molecule FBXO3 protein inhibitors. One of his compound designs, BC-1215, is currently used as a molecular tool for investigating the ubiquitination pathway.